Whitepaper and App Notes

Simoa® Immunoassays Enable Ultrasensitive Detection of Blood-Based Biomarkers for Parkinson’s Disease


Publication Brief

Parkinson’s disease (PD) is a progressive and debilitating neurodegenerative disorder that affects millions of
people worldwide. Therapeutic management can ease symptoms and slow progression, especially if implemented
in the early stages of the disease. However, traditional diagnostic methods are limited to detecting motor deficits,
which may not manifest until the later stages of the disease progression. This leaves a critical gap in identifying
asymptomatic patients who could benefit most from early therapeutic intervention. Download our flyer to learn more and to view a sampling of peer-reviewed studies employing Simoa® technology for Parkinson’s disease research.